Today, the EPO Enlarged Board of Appeal handed down decision G1/23, dealing with the treatment of complex commercially available products as prior art. G1/23 asked the EPO to answer several key questions:
-
Do commercially available products constitute valid prior art if their composition/internal structure cannot be analysed and reproduced?
-
Is technical information about the commercially available product (e.g. in the form of technical brochures) prior art if the product itself is not valid prior art?
-
How should analysable and reproducible be interpreted in this context?
Join our G1/23 experts James Snaith and Tom Hailes for this fast response webinar as they discuss the decision and what it means for your IP strategy.
This webinar will cover:
-
The background technical and legal facts of G1/23.
-
The new legal test in G1/23: when, and to what extent, complex products now constitute prior art.
-
Insights we can glean from the decision.
-
Practical implications, e.g. when to file, what’s patentable in view of the prior art landscape, how can you leverage the decision to attack or defend?
We hope you can join us!